Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3

Methodology|Interests|Funding|Corrections

Cycle record

Assessment cycle 2026 Q1 — page 3

Documents ratified in the 2026 Q1 assessment cycle, which ran from 1 January 2026 to 31 March 2026 and was ratified on 18 March 2026.

Documents ratified

83 documents · page 3 of 3

Trial abstract: SYNCHRONIZE-2-REGIONAL-CN

CEI-TR-0578Trial abstract2026-q1

Randomised, double-blind, placebo-controlled, phase 3 study of Survodutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no…

Very low17 May 2026
Trial abstract: MARITIDE-PH3-HEPATIC-IMP

CEI-TR-0599Trial abstract2026-q1

Phase 1 ascending dose, phase 1 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for…

Very low08 May 2026
Trial abstract: MARITIDE-PH3-BIOMARKER

CEI-TR-0678Trial abstract2026-q1

Randomised, double-blind, placebo-controlled, phase 3 study of Maridebart cafraglutide in obesity over as stated in the parent protocol. The Institute holds no reported…

Very low15 Jun 2026

page 3 of 3

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.